Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer

Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer

BackgroundPeripheral blood biomarkers to immunotherapy have attracted more and more attentions owing to noninvasive nature. This study was designed to identify a panel of tumor associated autoantibodies (TAAbs) in plasma to predict the clinical outcome of ICIs-based treatment in advanced NSCLC patie...

Full description

Bibliographic Details
Main Authors: Juan Zhou, Jing Zhao, Qingzhu Jia, Qian Chu, Fei Zhou, Xiangling Chu, Wencheng Zhao, Shengxiang Ren, Caicun Zhou, Chunxia Su
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
biomarker
autoantibody
tumor-associated antigen
immune checkpoint inhibitor
lung cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.625578/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.625578/full

Similar Items